Exact Mass: 317.0946
Exact Mass Matches: 317.0946
Found 73 metabolites which its exact mass value is equals to given mass value 317.0946,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N2-Monodes-methylnizatidine
N2-Monodes-methylnizatidine is a metabolite of nizatidine. Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid. (Wikipedia)
N-2-Mdmn
2-{2-[4-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]hydrazono}-2-(methylsulfonyl)acetonitrile
Methyl 2-cyano-3-(2-morpholino-5-nitrophenyl)acrylate
9(10H)-Acridinone, 1,4,5-trihydroxy-3,6-dimethoxy-10-methyl-
1, 3, 5-trihydroxy-2, 4-dimethoxy-10-methyl-10H-acridin-9-one|citruscridone
2,3-Dimethoxy-10-methyl-1,5,6-trihydroxyacridin-9(10H)-one
1,3,6-trihydroxy-4,5-dimethoxy-10-methylacridin-9-one
5,6-Dihydro-8,9-dimethoxypyrrolo[2,1-a]isoquinoline-2,3-dicarboxylic acid
2-quinolin-2-yl-1-[4-(trifluoromethyl)phenyl]ethanol
5-[(3,5-dimethoxybenzoyl)amino]-2-hydroxybenzoic acid
Imipenem
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
1-(4-(4-Nitro-3-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone
2-quinolin-4-yl-1-[4-(trifluoromethyl)phenyl]ethanol
Methyl 4-(4-(Bis(2-Chloroethyl)Amino)Phenyl)Butyrate
Benzoic acid, 4-[(3,5-dimethoxybenzoyl)amino]-2-hydroxy-
tert-butyl 4-[4-(chloromethyl)-1,3-thiazol-2-yl]piperazine-1-carboxylate
6-methoxy-N-(4-methoxyphenyl)quinazolin-4-amine,hydrochloride
N-[(3S)-1-Chloro-5-methyl-2-oxohexan-3-yl]-4-methylbenzene-1-sulfonamide
2-(2-Deoxy-beta-D-erythro-pentofuranosyl)-7-hydroxypyrimido(1,6-a)benzimidazol-1(2H)-one
4-Sulfonamide-[4-(thiomethylaminobutane)]benzamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-(methylamino)ethyl]-2-sulfanylidenepyrimidin-4-one
1-[4-[2-Nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone
2-[[1-(4-Chlorophenyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-1-butanol
1-(4-chlorophenyl)-N-(1-methoxypropan-2-yl)-4-pyrazolo[3,4-d]pyrimidinamine
2-[[2-furanyl(oxo)methyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide
N-(furan-2-ylmethyl)-N-[(Z)-(2-hydroxy-3-methoxyphenyl)methylideneamino]oxamide
(8E)-8-[(2-fluoroanilino)hydrazinylidene]-1,3-dimethylpurine-2,6-dione
N-[2-[(2Z)-2-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]-2-oxoethyl]furan-2-carboxamide
LY456236
LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM[1][3].
(4ar,7s)-6,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-5-methoxy-4a,7-dihydro-1λ⁴-chromen-1-ylium
atalafoline b
{"Ingredient_id": "HBIN017264","Ingredient_name": "atalafoline b","Alias": "NA","Ingredient_formula": "C16H15NO6","Ingredient_Smile": "CN1C2=C(C=CC(=C2O)OC)C(=O)C3=C1C(=C(C=C3O)OC)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1954","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
